Veeva Systems Inc. — Form 10-Q Summary
Reporting period: Second quarter and six months ended July 31, 2022; fiscal year ends January 31. Amounts are in U.S. dollars. Veeva provides cloud software, data, analytics, and services, primarily for the life sciences industry.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $534.2m (+17%) | $455.6m | $1,039.3m (+17%) | $889.2m |
| Subscription revenue | $428.6m (+17%) | $366.4m | $831.3m (+17%) | $707.6m |
| Professional services and other | $105.6m (+18%) | $89.2m | $208.0m (+15%) | $181.6m |
| Gross profit / margin | $382.5m / 72% | $333.5m / 73% | $748.1m / 72% | $650.9m / 73% |
| Operating income / margin | $101.1m / 18.9% | $124.6m / 27.4% | $228.8m / 22.0% | $253.1m / 28.5% |
| Net income | $90.6m | $108.9m | $190.7m | $224.4m |
| Diluted EPS | $0.56 | $0.67 | $1.17 | $1.38 |
| Cash provided by operations | $93.4m | $119.1m | $574.4m | $597.5m |
Revenue growth was driven by both product areas, with R&D Solutions contributing more of the subscription growth. For Q2, subscription revenue increased $44m from R&D Solutions and $18m from Commercial Solutions. For the first six months, the respective increases were $86m and $38m. R&D Solutions represented 47% of total revenue in the first half, up from 44% in fiscal 2022.
Balance sheet and liquidity
- At July 31, cash and cash equivalents were $1.14bn and short-term investments were $1.78bn, totaling approximately $2.92bn in cash, cash equivalents, and investments.
- Total assets were $4.12bn; total liabilities were $872.7m; stockholders’ equity was $3.24bn. The filing reports no borrowings or other financial debt; liabilities primarily include deferred revenue and lease obligations.
- Deferred revenue was $684.6m. Lease liabilities totaled approximately $63.5m, current and noncurrent.
- Management said existing cash, investments, and operating cash flow should meet working-capital and capital-expenditure needs for at least 12 months.
Material changes versus prior-year period
- Despite 17% revenue growth in both the quarter and first half, GAAP operating income and net income declined. Q2 operating income fell 19% and net income fell 17%; first-half operating income fell 10% and net income fell 15%.
- Operating expenses rose substantially: Q2 R&D increased 41%, sales and marketing 25%, and general and administrative 37%. Management attributed the increases mainly to hiring, compensation increases, and stock-based compensation; Q2 stock-based compensation was $96.0m versus $62.4m.
- Gross margin declined one percentage point to 72%, primarily because of lower professional-services margins. Professional-services gross margin was 17% in Q2 versus 24% a year earlier.
- The effective tax rate increased to 17.3% in Q2 from 13.8%, and to 20.5% for the first half from 13.4%, primarily due to lower excess tax benefits from equity compensation.
- First-half operating cash flow decreased $23m year over year. The company noted that the first fiscal quarter is seasonally strongest for collections and expected operating cash flow to be substantially lower in later quarters of fiscal 2023.
Outlook, commentary, and risks
- Management expected revenue and subscription revenue to continue growing in the second half of fiscal 2023, but said year-over-year growth would be pressured by foreign-exchange movements and macroeconomic factors, including reduced funding and spending in some customer segments and increased budget and project scrutiny. The filing provides no clear numerical revenue or earnings guidance.
- Management expects revenue growth rates to decline compared with the prior fiscal year. It also expects continued investment and higher operating expenses, including employee costs, R&D, sales and marketing, professional services, infrastructure, and litigation-related expenses. Compensation increases and inflationary pressure are contributing to cost growth.
- Cash flow is being affected by U.S. tax rules requiring capitalization and amortization of certain R&D expenses. The company reported a $37.9m first-half cash-flow impact from the tax-law change in its non-GAAP reconciliation and warned that the effect could continue if the rule is not modified.
- Foreign exchange reduced reported revenue in the first half, and management expected further revenue pressure during fiscal 2023. The investment portfolio had $27.0m of gross unrealized losses at July 31; management said it intended to hold securities to maturity and believed credit losses would be immaterial. A 100-basis-point interest-rate increase was estimated to reduce portfolio market value by $16m.
- COVID-19 had not materially harmed performance to date, but future effects remain uncertain. The company also identified risks from the Ukraine conflict, inflation, rising rates, life-sciences funding conditions, customer budget scrutiny, and potential reductions in pharmaceutical sales representatives, which could affect CRM demand.
- IQVIA litigation remains ongoing; Veeva said outcomes cannot be predicted or estimated meaningfully. Veeva’s counterclaims seek more than $200m in damages and injunctive relief, but no recovery is assured. Certain law-firm success fees may be payable depending on outcomes and were not accrued. In a separate Medidata case, the court ruled for Veeva after trial; Medidata’s reconsideration motion was denied in August 2022.
- Other stated risks include customer concentration, competition and adoption of newer products, data-provider restrictions, reliance on Salesforce and other technology providers, cybersecurity and privacy regulation, and the company’s PBC governance and dual-class voting structure.
Important facts for investors to verify
- Whether subscription growth and the increasing R&D contribution can offset slower growth or pressure on Commercial Solutions, including potential CRM seat reductions.
- How quickly operating expenses and stock-based compensation grow relative to revenue, and whether operating margins stabilize after the Q2 decline.
- Whether customer scrutiny, life-sciences funding conditions, and foreign-exchange headwinds affect bookings, renewals, and future revenue growth.
- The persistence and cash-flow impact of R&D tax amortization requirements, alongside the company’s seasonal cash-flow pattern.
- Developments in IQVIA and other litigation, related legal costs, and any potential settlement, judgment, or success-fee exposure.
- Changes in the value and composition of short-term investments, including interest-rate sensitivity and unrealized losses.